Opinion|Videos|October 19, 2023
Expert Perspectives on the VIOLETTE Study and Future Directions in Prostate Cancer Research
Author(s)Amir H. Lebastchi, MD
Amir H. Lebastchi, MD, provides perspectives on the VIOLETTE study and underscores the importance of future head-to-head trials to gain a deeper understanding of various treatment approaches.
Advertisement
Episodes in this series
Advertisement
Related to this article
Topline results from the study are anticipated in the first half of 2027.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.
In TALAPRO-3, talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide (HR, 0.48; P < .0001) in HRR-mutated mAPMN/S prostate cancer.
Interim phase 3 data show a 58% reduction in the risk of metastasis or death with the addition of darolutamide to ADT + radiation.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.
Advertisement
Advertisement
Trending on Urology Times
1
Novel RIPTAC molecule shows promising activity in heavily pretreated mCRPC
2
Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC
3
CLARIFY trial reaches enrollment target for 64Cu-SAR-bisPSMA in prostate cancer
4
LITESPARK-012: Lessons from a negative phase 3 trial in first-line RCC
5